Cite
Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial.
MLA
Kaye, Keith S., et al. “Fosfomycin for Injection (ZTI-01) Versus Piperacillin-Tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial.” Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 69, no. 12, Nov. 2019, pp. 2045–56. EBSCOhost, https://doi.org/10.1093/cid/ciz181.
APA
Kaye, K. S., Rice, L. B., Dane, A. L., Stus, V., Sagan, O., Fedosiuk, E., Das, A. F., Skarinsky, D., Eckburg, P. B., & Ellis-Grosse, E. J. (2019). Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 69(12), 2045–2056. https://doi.org/10.1093/cid/ciz181
Chicago
Kaye, Keith S, Louis B Rice, Aaron L Dane, Viktor Stus, Olexiy Sagan, Elena Fedosiuk, Anita F Das, David Skarinsky, Paul B Eckburg, and Evelyn J Ellis-Grosse. 2019. “Fosfomycin for Injection (ZTI-01) Versus Piperacillin-Tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial.” Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 69 (12): 2045–56. doi:10.1093/cid/ciz181.